Whitehawk Therapeutics, Inc.
WHWK
$4.16
$0.051.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -72.50% | -42.62% | -9.33% | 16.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -72.50% | -42.62% | -9.33% | 16.51% |
| Cost of Revenue | 101.40% | 69.69% | 66.96% | 54.96% | -9.43% |
| Gross Profit | -360.60% | -201.30% | -166.70% | -105.03% | 29.60% |
| SG&A Expenses | -40.18% | -18.85% | -2.87% | -7.70% | -11.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.96% | 33.86% | 38.57% | 28.38% | -10.32% |
| Operating Income | -102.73% | -76.49% | -70.58% | -41.09% | 18.89% |
| Income Before Tax | -519.37% | 67.66% | 74.68% | 84.08% | 140.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -519.37% | 67.66% | 74.68% | 84.08% | 140.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -519.37% | 67.66% | 74.68% | 84.08% | 140.12% |
| EBIT | -102.73% | -76.49% | -70.58% | -41.09% | 18.89% |
| EBITDA | -103.36% | -76.89% | -70.89% | -41.22% | 18.96% |
| EPS Basic | -1,124.79% | 120.71% | 106.53% | 97.60% | 106.40% |
| Normalized Basic EPS | 14.03% | 24.05% | 6.10% | 10.70% | 23.88% |
| EPS Diluted | -1,219.48% | 120.02% | 105.78% | 97.05% | 105.86% |
| Normalized Diluted EPS | 13.91% | 24.17% | 6.22% | 10.81% | 23.99% |
| Average Basic Shares Outstanding | 129.13% | 128.58% | 89.83% | 50.92% | 12.07% |
| Average Diluted Shares Outstanding | 128.58% | 128.85% | 90.10% | 51.19% | 12.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |